1 of 14

Khaled Abdel-Aziz Kamal�Ain Shams University�12th of December 2024

New era of adjuvant systemic therapy in endometrial cancer

2 of 14

Disclosure

Compensated advisory boards/Consultancy and/or speakers remuneration: Roche, MSD, Janssen, Sanofi, AstraZeneca, Bayer, Novartis, Eva-Lilly, Sandoz, Merck Serono, Pfizer

Meeting travel support: Roche, Janssen, Astrazeneca, Sanofi, Amgen, Astellas, Pfizer, Astellas, Takeda, Hikma

Clinical trial involvement: Roche, AstraZeneca, Novartis

PICE executive committee member

Medical Advisor to CORTEX Innovative Solutions

​

3 of 14

Title of Presentation | DD.MM.YYYY

3

4 of 14

Title of Presentation | DD.MM.YYYY

4

dMMR/MSI-H – In this subset with 118 patients, the PFS rate at 24 months was better with dostarlimab than placebo (PFS 61 versus 16 percent, respectively; HR 0.28, 95% CI 0.16-0.50). OS at 24 months was also improved at 83 percent with the dostarlimab group versus 59 percent with placebo (HR 0.30, 95% CI 0.13-0.70).

Only 24 patients with primary stage III disease had dMMR/MSI-H tumors. Of these, 4 of 10 patients in the dostarlimab group and 6 of 14 patients in the placebo group experienced progression (HR 0.92, 95% CI 0.26-3.3).

5 of 14

6 of 14

6

7 of 14

Title of Presentation | DD.MM.YYYY

7

8 of 14

Title of Presentation | DD.MM.YYYY

8

9 of 14

Title of Presentation | DD.MM.YYYY

9

10 of 14

Title of Presentation | DD.MM.YYYY

10

11 of 14

Title of Presentation | DD.MM.YYYY

11

12 of 14

Design of the RAINBO program.

RAINBO Research Consortium Int J Gynecol Cancer 2022;ijgc-2022-004039

© IGCS and ESGO 2022. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ.

13 of 14

13

14 of 14

Title of Presentation | DD.MM.YYYY

14